lutetium lu 177 dotatate

Lutetium Lu 177-dotatate has been given the green light for treating gastroenteropancreatic neuroendocrine tumors in adults with somatostatin receptor positive cancer.

In all published studies (Table 3), the toxicities associated with 177Lu PSMA therapy have generally been low grade. Dry mouth or xerostomia is reported by up to 30% of men after treatment, while fatigue is a common side effect in up to 25% of treated men.

The Lu-177 PSMA-617 RLT resulted in a notable reduction in PSA levels, with over half (50.6%) of patients experiencing a decrease of more than 50%. The median overall survival (OS) was 13.5 months, while the median progression-free survival was 8.2 months.

Lutetium, the least abundant lanthanide, is significantly outnumbered by cerium, the most abundant lanthanide, on Earth. As a result, lutetium and its compounds are quite costly. However, it is worth noting that lutetium is more abundant than elements such as silver, gold, and the platinum metals.

After treatment, it is important to shower daily for the first 7 days. You should also maintain a distance of 3 feet from others for 2-3 days, and specifically stay 3 feet away from children under 10 and pregnant individuals for 7 days. It is recommended to sleep in separate beds that are at least 3 feet apart and to avoid sexual activity for 7 days.

Lutetium is considered to have a low toxicity rating, but it can be mildly toxic if ingested. However, its insoluble salts are non-toxic. It is important to handle lutetium and its compounds with care, as with other rare-earth metals.

Lutetium is a form of treatment that uses radiation to target cancer cells. It works by attaching a molecule to the PSMA receptors found on the cancer cells. Lutetium-177 emits beta radiation, which is able to effectively harm and eventually eliminate the cancer cells.

Lutetium, similar to other rare-earth metals, is generally considered to have a low level of toxicity. However, it is still important to handle its compounds with caution. Inhaling lutetium fluoride can be hazardous and may cause skin irritation. Additionally, heating lutetium nitrate can lead to explosions and burns.

Lutathera has been shown to significantly extend progression-free survival in patients with progressive neuroendocrine pancreatic tumors. In a study with a median follow-up of 40 months, 80% of patients with unresectable tumors experienced no progression of their disease while receiving Lutathera.

Symptoms: hair loss, high blood pressure (hypertension), cough, and constipation.

Your urine may contain detectable levels of radiation for a period of 30 days after taking the medication. To ensure safety, it is recommended to follow the advice of your healthcare professional and take necessary precautions to minimize radiation exposure to people in your household.

Exposure to Radiation: Treatment with LUTATHERA adds to a patient’s total long-term radiation exposure and is linked to a higher risk of cancer.

According to the measured dosimetry, the spleen is the critical organ with (68)Ga-DOTATATE, followed by the uroepithelium of the bladder, kidneys, and liver, in that sequence.

Lutetium-177 (Lu-177) is a widely utilized medical isotope in targeted radionuclide therapy for the treatment of neuroendocrine tumors and prostate cancer. It is manufactured at NRG’s nuclear facility and is currently the predominant isotope employed in targeted radionuclide therapy.

After a median follow-up period of 15.9 months, it was found that patients who received Pluvicto treatment had a median progression-free survival of 12.02 months. On the other hand, patients who received a different ARPI treatment had a median progression-free survival of 5.59 months.

Lutetium-177 vipivotide tetraxetan, also known as PSMA-617 (LuPSMA), has been recently approved by the U.S. Food and Drug Administration as a therapy for patients with metastatic castration-resistant prostate cancer (mCRPC).

In the current study, it was found that the overall survival of mCRPC patients without RLT was expected to be approximately 11 months (25). However, the use of 177Lu-PSMA therapy appeared to extend patient survival, as only nine deaths were reported during the follow-up period of 26±7 months (equivalent to a 25% mortality rate over approximately two years).

When undergoing lutetium-177 PSMA therapy, certain patients may feel tired and nauseous. The radiation can affect the salivary glands, leading to dry mouth, as these glands, responsible for producing saliva, also express some PSMA, in addition to prostate cancer cells.

Lutetium is considered to have a low toxicity rating, but it should still be handled with care. While its insoluble salts are non-toxic, ingestion of lutetium can be mildly toxic. It is important to take precautions when dealing with lutetium and its compounds.

During the initial weeks following treatment, the radioactive material will exit your body through various bodily fluids such as blood, urine, saliva, and other body fluids.

The price of Pluvicto intravenous solution (1000 MBq/mL) can vary depending on the pharmacy you choose, but it is typically around $45,657 for a single supply.

To find the right Lutetium-177 therapy clinic for you, we recommend checking the hospital ranking based on requests and 4 reviews. The average price for this therapy is $10,454, with a minimum price of $9,362 and a maximum price of $12,000.

Individuals who have prostate cancer that has spread beyond the prostate and has not responded to other treatments, such as hormonal therapies and chemotherapy, may be considered as candidates for lutetium-177 PSMA therapy.

In the current study, it was found that the overall survival of mCRPC patients without RLT was expected to be approximately 11 months (25). However, the use of 177Lu-PSMA therapy appeared to extend patient survival, as only nine deaths were reported during the follow-up period of 26±7 months (equivalent to a 25% mortality rate over approximately two years).

In the Pluvicto group, there was a complete response rate of 21.1%, indicating the disappearance of all signs of cancer from treatment. In contrast, the ARPI change group had a complete response rate of only 2.7%.

The price of Pluvicto intravenous solution (1000 MBq/mL) can vary depending on the pharmacy you choose, but it is typically around $45,657 for a single supply.

The FDA has declared an end to the drug shortage of 177Lu vipivotide tetraxetan, allowing the targeted radioligand to be readily available in over 200 centers for patients with prostate cancer. The shortage, which was announced on March 7, 2023, has finally come to an end on October 25, 2023.

There was no significant difference in overall survival between individuals who were assigned to [177Lu]Lu-PSMA-617 and those who were assigned to cabazitaxel, with a RMST of 19.1 months (95% CI 16.9 to 21.4) and 19.6 months (17.4 to 21.8), respectively. The difference between the two groups was -0.5 months (95% CI -3.7 to 2.7), and the p-value was 0.77.

In Germany, German patients typically have their treatment expenses covered by their health insurance. The cost of Lutetium-PSMA therapy in Germany varies significantly depending on the clinic, with an average price of approximately 8000 euros per injection. Typically, patients receive between 2 and 6 injections.

What can you expect during treatment? The administration of LUTATHERA may be delayed until you are prepared, depending on the results. The infusion process typically takes approximately 5 hours.

Lutetium possesses the greatest Brinell hardness among all lanthanides, measuring between 890 and 1300 MPa.

Mechanism of Action: Lutetium Lu 177 dotatate has a strong affinity for subtype 2 receptors (SSRT2) found on somatostatin receptor expressing cells. When it binds to these cells, including malignant somatostatin receptor-positive tumors, the compound is taken inside the cells.

Generally, you will need to adhere to the following guidelines after treatment: Maintain a distance of 3 feet from others during the initial few days. Sleep alone for approximately 1 week. Refrain from holding or sharing a bed with small children or pregnant individuals for around 9 to 11 days.

Lutathera, the initial Peptide Receptor Radionuclide Therapy (PRRT) sanctioned for treating NETs in the United States, consists of two elements. These components include molecules that target the drug specifically to the tumors and radiation that aids in reducing and eliminating the tumor cells.

PRRT, although not a curative treatment, has demonstrated efficacy in alleviating symptoms, reducing tumor size, and slowing disease progression, as evidenced by the findings of the phase III NETTER trial published in the New England Journal of Medicine. However, it is important to note that like any other therapy, PRRT carries potential side effects and risks.

During the 2022 ESMO Congress, it was revealed that after a median follow-up of 40 months (95% CI, 35-43), Lutathera treatment led to an 80% 12-month PFS rate per blinded central review in the 41 patients who were administered the product.

The adverse reactions that occurred most frequently in grade 3/4 and had a higher incidence in the LUTATHERA arm were lymphopenia (44%), increased GGT (20%), vomiting (7%), nausea (5%), increased AST (5%), increased ALT (4%), hyperglycemia (4%), and hypokalemia (4%).

Lutetium-177 emits beta radiation as it undergoes decay, releasing high-energy electrons that the unstable atom cannot retain.

A PET/CT Ga-68 dotatate scan is a diagnostic procedure used to detect neuroendocrine tumors that affect the nervous system and endocrine glands. During the scan, a radioactive tracer called Ga-68 dotatate is injected into your vein.

DOTATATE, which is labeled with the radioisotope gallium 68, is administered intravenously in small quantities. Similar to octreotide, DOTATATE attaches to somatostatin receptors that are abundantly present in the majority of neuroendocrine tumors.